% | $
Quotes you view appear here for quick access.

Мабвакс Терапевтика Message Board

  • zpuix zpuix Dec 9, 2001 4:30 PM Flag

    Why the steady move up....

    What might be causing this stock
    to rise so steadily these past weeks.
    Very consistant move upward. Is
    there a buyout coming perhaps?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From website: M. Li (et al), (2001), "Small Molecule Insulin Receptor Activators Potentiate Insulin Action in Insulin Resistant Cells", Diabetes (in press).

    • J Comb Chem 2001 Nov-Dec;3(6):572-7

      Traceless, Self-Cleaving Solid- and Solution-Phase Parallel Synthesis of 3,4,7-Trisubstituted 3,4-Dihydroquinoxalin-2-ones.

      Laborde E, Peterson BT, Robinson L.

      Telik, Inc., 750 Gateway Boulevard, South San Francisco, California 94080.

      This article describes a new methodology for the parallel synthesis of 3,4-dihydroquinoxalin-2-ones containing three points of diversity. The synthesis begins with commercially available resin-bound alpha-amino acids as the source of the first diversity element and employs a combination of solid- and solution-phase chemistry to introduce the other two. The key step is an intramolecular cyclization and simultaneous traceless cleavage from the solid support to give a disubstituted 3,4-dihydroquinoxalin-2-one. The third substituent is introduced in solution by N-alkylation of the aniline nitrogen using a scavenger resin to dispose of excess reagent. All the reactions in the sequence take place at room temperature without the need to use strong acids or to maintain an inert atmosphere, thereby preserving the chiral integrity of the starting alpha-amino acid and facilitating the generation of libraries in a high-throughput parallel format.